Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  367 results for ""Lung Neoplasms""

Your Filters

Content Provider : MEDLINE Publication : cancer chemotherapy and pharmacology Format : Academic Journals Format : Reviews Subject : carcinoma, non-small-cell lung
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).

  • Authors : Hasegawa T; Division of Respiratory Disease, Department of Internal Medicine, The Jikei University Daisan Hospital, Tokyo, Japan.; Ariyasu R

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Antineoplastic Agents, Immunological*

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Jul; Vol. 92 (1), pp. 29-37. Date of Electronic Publication: 2023 May 27.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.

  • Authors : de Rouw N; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.; Department of Pharmacy, Jeroen Bosch Hospital, 'S-Hertogenbosch, The Netherlands.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/metabolism

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Jan; Vol. 91 (1), pp. 33-42. Date of Electronic Publication: 2022 Nov 21.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.

  • Authors : Kitano S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. .; Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan. .

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/drug therapy

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Dec; Vol. 90 (6), pp. 523-529. Date of Electronic Publication: 2022 Oct 26.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.

  • Authors : Kenmotsu H; Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Aug; Vol. 90 (2), pp. 115-123. Date of Electronic Publication: 2022 Jul 12.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.

  • Authors : Nakagawa K; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama City, 377-2, Ohno-higashi, Osaka, 589-8511, Japan. .; Kindai University Faculty of Medicine, Osaka, Japan. .

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Hypertension*

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Aug; Vol. 90 (2), pp. 137-148. Date of Electronic Publication: 2022 Jul 16.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies.

  • Authors : Xue J; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 East Dongfeng Road, Guangzhou, 510060, China.; He H

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/pathology

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Sep; Vol. 90 (3), pp. 229-237. Date of Electronic Publication: 2022 Aug 03.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer.

  • Authors : Barlesi F; Marseille Early Phases Cancer Trials Center CLIP, Aix Marseille University, APHM, Marseille, France.; SMARTc Unit Centre de Recherche en Cancérologie de Marseille Inserm U1068, Aix Marseille University, Marseille, France.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/pathology ; Neutropenia*/Neutropenia*/Neutropenia*/chemically induced

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Aug; Vol. 90 (2), pp. 149-160. Date of Electronic Publication: 2022 Jul 22.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.

  • Authors : Xiong W; Merck Institute of Pharmacometrics, Lausanne, Switzerland.; Hietala SF

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/pathology; Edema

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jul; Vol. 90 (1), pp. 53-69. Date of Electronic Publication: 2022 Jun 30.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.

  • Authors : Xiong W; Merck Institute of Pharmacometrics, Merck KGaA, Lausanne, Switzerland.; UCB, Bulle, Switzerland.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 May; Vol. 89 (5), pp. 655-669. Date of Electronic Publication: 2022 Apr 06.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.

  • Authors : Felip E; Thoracic Cancer Unit, Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Moreno V

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Melanoma*/Melanoma*/Melanoma*/drug therapy

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Apr; Vol. 89 (4), pp. 499-514. Date of Electronic Publication: 2022 Mar 17.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  367 results for ""Lung Neoplasms""